Literature DB >> 6159865

Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects.

P Thorén, M Asberg, L Bertilsson, B Mellström, F Sjöqvist, L Träskman.   

Abstract

Concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA), the dopamine metabolite homovanillic acid, and the noradrenaline metabolite 4-hydroxy-3-methoxyphenyl glycol were measured in CSF before and after three weeks' treatment of severe obsessive-compulsive disorder with clomipramine hydrochloride. Patients who responded to clomipramine treatment had significantly higher CSF levels of 5-HIAA before treatment. The amelioration of obsessive-compulsive symptoms was positively correlated to the reduction of CSF concentrations of 5-HIAA during clomipramine treatment but negatively correlated to plasma concentrations of clomipramine. Reduction of CSF concentrations of 5-HIAA, which probably reflects drug action on central serotonin neurons, was maximal at a plasma clomipramine concentration of about 300 nmole/L. At higher levels, the reduction of CSF levels of 5-HIAA was smaller. The antiobsessive effect of clomipramine may be connected to its capacity to inhibit serotonin uptake.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6159865     DOI: 10.1001/archpsyc.1980.01780240087010

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  19 in total

1.  Effect of clomipramine on monoamine metabolites in the cerebrospinal fluid of behaviorally normal dogs.

Authors:  C J Hewson; U A Luescher; J M Parent; R O Ball
Journal:  Can J Vet Res       Date:  2000-04       Impact factor: 1.310

Review 2.  Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder.

Authors:  D McTavish; P Benfield
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

3.  Monoamine abnormalities in the SAPAP3 knockout model of obsessive-compulsive disorder-related behaviour.

Authors:  Jesse Wood; Zoe LaPalombara; Susanne E Ahmari
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-03-19       Impact factor: 6.237

4.  Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study.

Authors:  M Reimold; M N Smolka; A Zimmer; A Batra; A Knobel; C Solbach; A Mundt; H U Smoltczyk; D Goldman; K Mann; G Reischl; H-J Machulla; R Bares; A Heinz
Journal:  J Neural Transm (Vienna)       Date:  2007-08-22       Impact factor: 3.575

5.  Drug treatment of obsessive-compulsive disorder.

Authors:  P T Lelliott; W O Monteiro
Journal:  Drugs       Date:  1986-01       Impact factor: 9.546

6.  Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results.

Authors:  Silvio R Bareggi; L Bianchi; R Cavallaro; M Gervasoni; F Siliprandi; L Bellodi
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

7.  Clomipramine in obsessive-compulsive ritualisers treated with exposure therapy: relations between dose, plasma levels, outcome and side effects.

Authors:  Y Kasvikis; I M Marks
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 8.  Current concepts in the pharmacological treatment of obsessive-compulsive disorder.

Authors:  J Zohar; R C Zohar-Kadouch; S Kindler
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 9.  Eating disorder and obsessive-compulsive disorder: neurochemical and phenomenological commonalities.

Authors:  J L Jarry; F J Vaccarino
Journal:  J Psychiatry Neurosci       Date:  1996-01       Impact factor: 6.186

Review 10.  Clinical investigation of monoamine neurotransmitter interactions.

Authors:  J K Hsiao; W Z Potter; H Agren; R R Owen; D Pickar
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.